|
Depressed mood
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There was no relationship between baseline E2F1 levels and depression severity, response to treatment, presence of psychosis or polarity of depression.
|
30365982 |
2019 |
|
Nonorganic psychosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
There was no relationship between baseline E2F1 levels and depression severity, response to treatment, presence of psychosis or polarity of depression.
|
30365982 |
2019 |
|
Squamous cell carcinoma of tongue
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that MPRL expression was significantly upregulated in TSCC cell lines treated with cisplatin and transactivated by E2F1.
|
30885939 |
2019 |
|
Infantile Severe Myoclonic Epilepsy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The transcription factors FOXM1 and E2F1, positive regulators of the disrupted pathways for histone modification and cell cycle regulation, were markedly up-regulated in DS-iPSC GABA lines.
|
31445158 |
2019 |
|
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Collectively, these data identify the E2F1-MFN2 axis as a regulator of mitochondrial morphology and mitophagy, suggesting a potential therapeutic target for the treatment of mitochondrial disorders.
|
31276298 |
2019 |
|
Post MI
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cardiac dysfunction was significantly attenuated at 1-week post-MI in E2f1-ablated mice.
|
31152247 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
6SL demonstrated anti-proliferative effects in a testosterone-induced BPH rat model and on BPH-1 cells by regulating the pRB/E2F1-AR pathway.
|
31547405 |
2019 |
|
Carcinoma of urinary bladder, invasive
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
|
30684846 |
2019 |
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The transcription factors FOXM1 and E2F1, positive regulators of the disrupted pathways for histone modification and cell cycle regulation, were markedly up-regulated in DS-iPSC GABA lines.
|
31445158 |
2019 |
|
Promyelocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
E2f1 regulates the induction of promyelocytic leukemia zinc finger transcription in neuronal differentiation of pluripotent P19 embryonal carcinoma cells.
|
30914194 |
2019 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.
|
29925919 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Jieduan-Niwan Formula Reduces Liver Apoptosis in a Rat Model of Acute-on-Chronic Liver Failure by Regulating the E2F1-Mediated Intrinsic Apoptosis Pathway.
|
31827563 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together with our previous finding that E2F1 promotes hepatic steatosis, the data presented here show that E2F1 contributes to both hyperlipidemia and hyperglycemia in diabetes, suggesting that specifically targeting E2F1 in the liver could be an interesting strategy for therapies against type 2 diabetes.
|
29526568 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Together with our previous finding that E2F1 promotes hepatic steatosis, the data presented here show that E2F1 contributes to both hyperlipidemia and hyperglycemia in diabetes, suggesting that specifically targeting E2F1 in the liver could be an interesting strategy for therapies against type 2 diabetes.
|
29526568 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together with our previous finding that E2F1 promotes hepatic steatosis, the data presented here show that E2F1 contributes to both hyperlipidemia and hyperglycemia in diabetes, suggesting that specifically targeting E2F1 in the liver could be an interesting strategy for therapies against type 2 diabetes.
|
29526568 |
2018 |
|
Gonorrhea
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study indicates that NNT-AS1 sponges miR-424/E2F1 to facilitate GC tumorigenesis and cycle progress, revealing the oncogenic role of NNT-AS1 for GC.
|
30006956 |
2018 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We study the impact of depleting E2F1 or inhibiting E2F1 activity in diabetic mouse models to evaluate if this transcription factor contributes to hyperglycemia during insulin resistance.
|
29526568 |
2018 |
|
Hyperlipidemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together with our previous finding that E2F1 promotes hepatic steatosis, the data presented here show that E2F1 contributes to both hyperlipidemia and hyperglycemia in diabetes, suggesting that specifically targeting E2F1 in the liver could be an interesting strategy for therapies against type 2 diabetes.
|
29526568 |
2018 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of the P16 protein in lung tissues was enhanced, while cyclin D1 and E2F1 protein were reduced by 5-aza-CdR treatment during hyperoxia.ConclusionThese data show that 5-aza-CdR attenuated lung fibrosis in neonatal rats exposed to hyperoxia by lowering hydroxyproline and TGF-β1 expression and via re-expression of P16 in neonatal rats.
|
29166374 |
2018 |
|
Malignant neoplasm of oropharynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy.
|
29574328 |
2018 |
|
Liposarcoma, Myxoid
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The in vitro and in vivo treatment of myxoid liposarcoma with trabectedin, a drug with a potent anti-tumor activity, revealed downregulation of HMGA1, E2F1, and its-downstream targets, vimentin and ZEB1, indicating a critical role of trabectedin in inhibiting the mesenchymal markers of these tumors through the HMGA1/E2F1 axis.
|
29980789 |
2018 |
|
Neuroendocrine Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
|
27871087 |
2018 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDK2, CDKN1A, E2F1 and MYC were indicated as the potential feature genes in metastatic breast cancer.
|
29328377 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our findings reveal that the rs3213173 (C/T) and rs3213176 (G/A) polymorphisms of the E2F1 gene are genetic risk factors for susceptibility to LC and HNC in the North Indian Population.
|
30036075 |
2018 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The microarray experiment revealed that RSV significantly increased TTP expression by downregulating E2F transcription factor 1 (E2F1), a downstream target gene of TTP and regulated genes associated with inflammation, cell proliferation, cell death, angiogenesis and metastasis.
|
29956753 |
2018 |